Analyst firms · J.P. Morgan · KPTI

J.P. Morgan KPTI price target and rating history

Karyopharm Therapeutics Inc. (KPTI) · Health Care

J.P. Morgan rates Karyopharm Therapeutics Inc. (KPTI) Neutral with a $8 price target, as of its latest action on Feb 9, 2022. It has published 3 rating actions on KPTI since August 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a KPTI price target in the last 12 months, the median target is $3.

Current rating
Neutral
Price target
$8
Median target, all firms
$3
Actions on KPTI
3

Every J.P. Morgan rating on KPTI

How other firms rate KPTI

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightNeutral$3Jul 31, 2026
Robert W. BairdNeutral$3Jul 31, 2026
Rodman & RenshawBuy$28Mar 10, 2026
Cantor FitzgeraldOverweightFeb 5, 2026

Questions about J.P. Morgan and KPTI

What is J.P. Morgan's price target for KPTI?
J.P. Morgan's latest stated price target for Karyopharm Therapeutics Inc. (KPTI) is $8, from its action on Feb 9, 2022.
What is J.P. Morgan's rating on KPTI?
J.P. Morgan rates KPTI Neutral, a neutral rating, as of Feb 9, 2022.
When did J.P. Morgan last change its view on KPTI?
On Feb 9, 2022, J.P. Morgan upgrades to Neutral from Underweight, price target $8.
How does J.P. Morgan's KPTI target compare with other analysts?
Across 3 firms with a KPTI price target in the last 12 months, the median target is $3.

More KPTI rating histories

All J.P. Morgan ratingsKPTI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.